poisar

Stocks · News reference

Akari Therapeutics shares are trading higher after the company highlighted progress toward AKTX-101 Phase 1 development and growing demand for its PH1 ADC payload platform.

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AKTX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Akari Therapeutics Plc (AKTX)

    Filed: 2026-10-01 AccNo: 0001493152-26-045364 Size: 289 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

    AKTX